- DermTech press release ( NASDAQ: DMTK ): Q3 GAAP EPS of -$0.96 beats by $0.03 .
- Revenue of $3.57M (+17.8% Y/Y) misses by $1.1M .
- Billable sample volume grew 54 percent from the third quarter of 2021 to approximately 18,080.
- Assay revenue was $3.4 million, up 16 percent from the third quarter of 2021, primarily due to higher billable sample volume.
- Cash, cash equivalents, restricted cash and short-term marketable securities were $152.8 million as of September 30, 2022.
- Shares -5% .
For further details see:
DermTech GAAP EPS of -$0.96 beats by $0.03, revenue of $3.57M misses by $1.1M